Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Article and Video CATEGORIES
Denise has over 30 years of varying experience in the healthcare arena. In August 2009 she joined The Global Resource for Advancing Cancer Education as one of its first employees. She has grown with the organization and now oversees the operational movement of programs, efficiency, and effectiveness within the organization, as well as the daily processes and functions.
No Hesitation -- Patient Perspectives Clinical Trials Storytelling 2023-24
dbrock
Amy Whitecotton shares her story for the Patient Perspectives Clinical Trials Storytelling 2023-24 Program.
Image
Amy’s story is shared as part of the Patient Perspectives - Clinical Trials Experiences Storytelling Program
This program aims to give those diagnosed with cancer a voice to share their experiences participating in clinical trials and help others understand the importance of participating in clinical trials. To view the full playlist of videos from the Patient Perspectives - Clinical Trials Storytelling Program, please visit the full playlist for this program here.
"No Hesitation" is Amy's story.
Diagnosed with Invasive Ductal Carcinoma (Triple Negative) in the fall of 2020, Amy was asked at her diagnosis if she would be willing to participate in a clinical trial, and she immediately agreed without hesitation. She has participated in the ARTEMIS trial through MD Anderson, and a trial of Enzalutamide and Paclitaxel Before Surgery. She has also participated in mental health studies and trials specifically for people who have been through a cancer diagnosis, through Stanford Cancer Center. This study worked to help understand how your mindset might affect one's health and well-being. She continues to participate in a study called Breaking Through the Brain Fog at the University of Texas at Dallas, focusing on education, exercises, and strategies to support brain health.
Amy's story is one of success, and not hesitating to move forward with clinical trials that saved her life.
A huge thanks to our sponsors! #exelixis #lilly #merck #blueprintmedicines
Video Language
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Image
Video
In this series, the 2024-25 Clinical Trials Experiences Through Storytelling Program, we talk to cancer survivors who have a passion for telling their stories in order to help others who may be navigating the clinical trials experience.
In this 2nd series of videos, Michael Herman takes us through the story of his diagnosis, his struggles with treatment options, his clinical trial and his learning curve.
Thank you to our Sponsors! #lilly #exelixis
Image
Video
In this series, the 2024-25 Clinical Trials Experiences Through Storytelling Program, we talk to cancer survivors who have a passion for telling their stories in order to help others who may be navigating the clinical trials experience.
Image
Article
Tell your story and help us help others! Apply online now for this paid opportunity. This program gives a voice to those who have experience in participating in a clinical trial for a cancer diagnosis. Your voice helps to educate and advocate for others who are in or who may be considering a clinical trial. We want to hear from you!
Online Community
Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".
While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".
I hope any...
My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:
- The antibody, which serves as the “horse,” specifically targets a protein found on cancer...
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
A Brief Tornado. I love the analogy Dr. Antonoff gave us to describe her presentation. I felt it earlier too and am looking forward to going back for deeper dive.